Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy.
Cingolani A, Tavelli A, Maggiolo F, Perziano A, Saracino A, Vichi F, Cernuschi M, Guaraldi G, Quiros-Roldan E, Castagna A, Antinori A, d'Arminio Monforte A, On Behalf Of Icona Foundation Study Group. Cingolani A, et al. Among authors: saracino a. J Clin Med. 2022 Jan 17;11(2):471. doi: 10.3390/jcm11020471. J Clin Med. 2022. PMID: 35054165 Free PMC article.
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Torti C, et al. Among authors: saracino a. J Med Virol. 2004 Sep;74(1):29-33. doi: 10.1002/jmv.20142. J Med Virol. 2004. PMID: 15258965
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G. Saracino A, et al. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98. doi: 10.1097/00126334-200412150-00011. J Acquir Immune Defic Syndr. 2004. PMID: 15577415 Clinical Trial.
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis.
Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, Moioli C, Rizzardini G, Chiodera A, Ballardini G, Tincati C, d'Arminio Monforte A; I.Co.N.A. Study Group. Cicconi P, et al. Infection. 2008 Feb;36(1):46-53. doi: 10.1007/s15010-007-6300-z. Epub 2008 Jan 29. Infection. 2008. PMID: 18231722
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort. Di Giambenedetto S, et al. Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7. Infection. 2009. PMID: 19669091
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Torti C, et al. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. BMC Infect Dis. 2011. PMID: 21266068 Free PMC article. Clinical Trial.
Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010.
Sulis G, El Hamad I, Fabiani M, Rusconi S, Maggiolo F, Guaraldi G, Bozzi G, Bernardini C, Lichtner M, Stentarelli C, Carenzi L, Francisci D, Saracino A, Castelli F; HIV/Migrants Study Group. Sulis G, et al. Among authors: saracino a. Infection. 2014 Oct;42(5):859-67. doi: 10.1007/s15010-014-0648-7. Epub 2014 Jun 29. Infection. 2014. PMID: 24973981
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.
Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study. Lichtner M, et al. Among authors: saracino a. J Infect Dis. 2015 Jan 15;211(2):178-86. doi: 10.1093/infdis/jiu417. Epub 2014 Jul 31. J Infect Dis. 2015. PMID: 25081936
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Postorino MC, Prosperi M, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Saracino A, Costarelli S, Lorenzotti S, Sighinolfi L, Di Pietro M, Torti C; MASTER Study Group. Postorino MC, et al. Among authors: saracino a. Clin Microbiol Infect. 2015 Apr;21(4):386.e1-9. doi: 10.1016/j.cmi.2014.10.022. Epub 2014 Nov 11. Clin Microbiol Infect. 2015. PMID: 25595708 Free article.
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.
Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E; MASTER Cohort. Raffetti E, et al. Among authors: saracino a. BMC Public Health. 2015 Mar 12;15:235. doi: 10.1186/s12889-015-1565-0. BMC Public Health. 2015. PMID: 25884678 Free PMC article.
427 results